<DOC>
	<DOCNO>NCT03022045</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy two different dose regimen risankizumab Japanese subject generalize pustular psoriasis ( GPP ) erythrodermic psoriasis ( EP ) .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Two Different Dose Regimens Risankizumab Administered Subcutaneously Japanese Subjects With Generalized Pustular Psoriasis Erythrodermic Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>For generalize pustular psoriasis Have diagnosis generalize pustular psoriasis least 60 day prior inform consent base diagnostic criterion Japanese Dermatological Association ( JDA ) . Subjects fulfil one diagnostic criterion i.e. , `` accompany systemic symptom include fever malaise '' time screen enter . Subjects erythema area pustule account ≥ 10 % body surface area ( BSA ) , severity assessment criterion score ( JDA total score ) specify JDA le 14 . Must candidate systemic therapy phototherapy generalize pustular psoriasis , assess investigator . For erythrodermic psoriasis Have diagnosis erythrodermic psoriasis prior inform consent . Subjects inflammatory erythema area accounting ≥ 80 % BSA screening time first administration study drug . Must candidate systemic therapy phototherapy erythrodermic psoriasis , assess investigator . Previous exposure risankizumab . Currently enrol another investigational study le 30 day ( screen ) since complete another investigational study ( participation observational study permit ) . For generalized pustular psoriasis Subjects active ongoing inflammatory disease generalize pustular psoriasis might confound trial evaluation accord investigator 's judgment . For erythrodermic psoriasis Subjects active ongoing inflammatory disease erythrodermic psoriasis might confound trial evaluation accord investigator 's judgment . Subject diagnose medicationinduced medicationexacerbated EP .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>risankizumab</keyword>
	<keyword>Erythrodermic Psoriasis</keyword>
	<keyword>Japanese</keyword>
	<keyword>Generalized Pustular Psoriasis</keyword>
</DOC>